SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending after its strong Q2 earnings beat and raised FY26 revenue guidance, fueling a community debate: many view the AI infrastructure leader as massively undervalued with short squeeze potential, while others focus on persistent margin compression and alleged market manipulation.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending after reporting strong Q4 earnings and optimistic long-term data center growth projections. However, a significant after-hours dip, stemming from Q1 guidance that exceeded consensus but missed elevated AI expectations, fuels community debate between those identifying a 'buy the dip' opportunity and concerns about overvaluation within the semiconductor sector.

"What's Updog?" is a Community Led token.

UpDog

UPDOG is trending, driven by its community leveraging the "What's UpDog?" joke and "The Dog Stays Up" mantra. Investors are actively encouraged to join this long-standing Solana meme coin, with discussions highlighting the potential for substantial gains.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is experiencing an extreme sell-off and record trading volume, fueled by market concerns that new AI productivity tools threaten traditional software models, prompting community discussion around potential capitulation and the sector being deeply oversold.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle Mexican Grill is trending after its Q4 earnings showed revenue and EPS beats, but a flat comparable sales forecast for 2026 fueled community concerns over management's outlook, menu pricing, and perceived shrinking portion sizes, creating strong debate on its immediate trajectory.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is surging after its Q4 earnings surpassed expectations and offered an improved outlook, igniting widespread relief and discussions of a significant turnaround for the solar stock. The positive news, combined with substantial short interest, is fueling community speculation of a short squeeze and renewed optimism for Enphase's new product lines and the broader solar sector.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending following an earnings miss and a sudden CEO change that triggered a sharp sell-off. The community is actively debating if the stock is a deep value opportunity despite its struggles against competitors and concerns surrounding the new leadership's strategic vision.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology is trending after reporting strong earnings and an upbeat outlook, driven by overwhelming AI and cloud demand that has booked its high-capacity storage through 2026 and beyond. The community is buzzing about this "memory supercycle" while some debate the stock's recent parabolic rise.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending due to the departure of its Chief Business Officer and an accelerated shareholder meeting, fueling community speculation about an imminent buyout or partnership for its MASH/obesity drug, pemvidutide. While many view these as bullish strategic moves by new CEO Jerry Durso, others express caution, questioning if the company is preparing for a "go it alone" Phase 3 strategy, despite a recent "Strong Buy" rating from Jefferies.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amidst anticipation for its upcoming Eagle Line inauguration event and earnings report, with community discussions buzzing about potential new OEM partnerships and a strategic board appointment signaling a shift towards commercial scaling of its solid-state battery technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The strategic review comes after Neuphoria discontinued advancing its lead drug candidate called BNC210 for the treatment of social anxiety disorder in October.</li><li>Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions, the company said.</li><li>The company said it will carefully evaluate and consider Lynx1 Master Fund’s indication of interest in connection with its review of strategic alternatives.</li></ul> Neuphoria Therapeutics Inc. (NEUP) initiated a review of strategic alternatives, including potential acquisitions, on Tuesday to advance its pipeline programs and maximize shareholder value.NEUP shares traded 4% higher in the pre-market session at the time of writing.<h2 class="st-heading-2">Strategic Alternatives Under Consideration</h2>Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.neuphoriatx.com/news-releases/news-release-details/neuphoria-announces-initiation-strategic-review-maximize">said.</a>The company added that it does not have a defined timeline for exploring strategic alternatives. Further, it is not confirmed that the process will result in a transaction.The strategic review comes after Neuphoria discontinued advancing its lead drug candidate called BNC210 for the treatment of social anxiety disorder in October after a late-stage trial missed its primary and secondary endpoints. Neuphoria then also said it will assess new development paths for BNC210 as a treatment for post-traumatic stress disorder (PTSD).<h2 class="st-heading-2">Lynx1 Master Fund Expresses Interest</h2>Neuphoria on Tuesday also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. The company said it will carefully evaluate and consider this indication of interest in connection with its review of strategic alternatives.Lynx1 Master Fund LP also expressed intent to nominate certain individuals to stand for election to Neuphoria’s Board of Directors at the company’s 2025 Annual Meeting of Stockholders, the company said. Neuphoria’s Board of Directors will now review the proposed director nominees. The annual meeting is scheduled for December 12.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NEUP">NEUP stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:623/62;" src="data:image/png;base64,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" width="623" height="62" alt="NEUP's Sentiment Meter and Message Volume as of 8:28 a.m. ET on Nov. 11, 2025 | Source: Stocktwits"><figcaption>NEUP's Sentiment Meter and Message Volume as of 8:28 a.m. ET on Nov. 11, 2025 | Source: Stocktwits</figcaption></figure>NEUP stock is up by 43% this year and by 11% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/poet-technologies-and-quantum-computing-team-up-to-boost-ai-data-speeds/cLPdoHVREPl">POET Technologies And Quantum Computing Team Up To Boost AI Data Speeds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition

Neuphoria also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. 

Equity

<ul class="summary-bullets"><li>Lynx1 Capital Management LP boosted its stake in Neuphoria Therapeutics by acquiring 639,110 shares.</li><li>The shares were bought at prices ranging from $4.96 to $5.20, with an average cost of $5.137 per share.</li><li>On Monday, Nuphoria&nbsp;announced a comprehensive strategic review of its business operations and pipeline.</li></ul>Neuphoria Therapeutics Inc. (NEUP) stock drew heightened attention from retail investors after prominent investor Lynx1 Capital Management LP increased its stake by acquiring 639,110 shares.The share purchase, made on October 21, was disclosed in a Securities and Exchange Commission (SEC)&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1191070/000090266425004536/xslF345X05/ownership.xml">filing</a>.&nbsp;<h2 class="st-heading-2">Pricing Details&nbsp;</h2>The shares were bought at prices ranging from $4.96 to $5.20, with an average cost of $5.137 per share. In total, Lynx1 Capital spent $3.3 million to expand its position.&nbsp;Following this acquisition, the investment firm now&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1191070/000090266425004537/xslSCHEDULE_13D_X01/primary_doc.xml">controls&nbsp;</a>875,328 shares of Neuphoria Therapeutics. The transaction highlights growing investor confidence in Neuphoria’s pipeline and market potential.<a href="https://stocktwits.com/symbol/NEUP">Neuphoria Therapeutics’ stock</a> traded over 64% higher on Friday morning and was the second-most trending equity ticker on Stocktwits. Retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.Neuphoria focuses on creating treatments for neuropsychiatric conditions. Its main drug candidate, BNC210, is an anti-anxiety therapy designed to rebalance brain neurotransmitters and deliver fast relief from anxiety and stress without causing sedation, cognitive issues, or dependency.AFFIRM-1 Phase 3 Trial Update&nbsp;On Monday, Neuphoria said its late-stage clinical trial for the drug BNC210 did not meet the main or secondary goals in treating patients with social anxiety disorder (SAD). The company announced the findings from its Phase 3 AFFIRM-1 study, which measured changes in anxiety levels using the Subjective Units of Distress Scale (SUDS) during a public speaking challenge.However, building on earlier positive data from studies involving chronic daily dosing, Neuphoria said it will assess new development paths for BNC210 as a treatment for post-traumatic stress disorder (PTSD).&nbsp;The company had also announced a comprehensive strategic review of its business operations and pipeline, with an update expected by the end of 2025.Neuphoria stock has gained over 78% in 2025 and over 41% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-neup-stock-surge-64-today/cLGJpuSR3tJ">Why Did NEUP Stock Surge 64% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pfizer scientist Larry James works with Western blots for a schizophrenia cognition deficits project in the neuroscience & pain lab.

Why Did NEUP Stock Surge 64% Today?

Lynx1 Capital Management LP boosted its stake in Neuphoria Therapeutics by acquiring 639,110 shares.

Shares of Neuphoria Therapeutics Inc. soared more than 11% in premarket trading on Wednesday, propelling the micro-cap biotech stock into the top 10 trending symbols on Stocktwits.&nbsp;The company is set to receive a $15 million milestone payment from Merck, triggered by the latter's initiation of a Phase 2 clinical trial to assess the safety and efficacy of MK-1167, an experimental drug for Alzheimer's disease dementia.&nbsp;This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments, along with royalties on any licensed medicines.Investors on the platform have expressed enthusiasm, with one user speculating that the stock could reach double digits soon, while another suggested it should ideally trade at more than triple its current levels.<stembedurl>https://stocktwits.com/Tigerphoenix/message/603914417</stembedurl><stembedurl>https://stocktwits.com/Realtrader77/message/603914418</stembedurl>Neuphoria, which has a market cap of just over $7.2 million, saw an 86% jump in following over the past month and a 1,200% increase in message volume on Stocktwits in the last week.&nbsp;Earlier in the month, H.C. Wainwright raised its price target on Neuphoria to $21 from $8, maintaining a 'Buy' rating.&nbsp;The research firm said its valuation argument was based on the company's progress with its broad-spectrum anti-anxiety therapeutic, BNC210.&nbsp;According to Koyfin data, at the end of the September quarter, Neuphoria had approximately $8 million in cash and investments and total debt under $220,000.&nbsp;<a href="https://stocktwits.com/symbol/NEUP">Neuphoria's stock</a> has lost more than 63% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes

This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $GOOGL earnings on Wednesday?

Current Price	$4.03
Prev Close	$4.04
Open	$4.04
Dividend Yield	0.00%
50-Day Moving Average	$4.09
Beta	0.98
Avg. Volume	46,762.45
PE Ratio	-0.17

52-Week High	$21.40
52-Week Low	$3.65
Market Capitalization	$21.72M
EPS (Annual)	-$0.2278
Price to Book	0.76
Revenue Per Employee	$1.96M
Enterprise Value/EBITDA	N/A

NEUP
Neuphoria Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest NEUP News

NEUPNeuphoria Therapeutics Inc.